Sporadic inclusion-body myositis: Conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-β42 oligomers and phosphorylated tau

Presse Medicale

Volumn 40, Issue 4, 2011, Pages

  Askanas, Valerie ^a   Engel, W King ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; HEAT SHOCK PROTEIN; MYOSTATIN; OLIGOMER; PARKIN; PROTEASOME; PROTEIN P62; SIRTUIN 1; TAR DNA BINDING PROTEIN; TAU PROTEIN; UBIQUITIN;

AGING; ALZHEIMER DISEASE; CELL VACUOLE; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON MICROSCOPY; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; HUMAN; INCLUSION BODY MYOSITIS; INTRACELLULAR TRANSPORT; LYSOSOME; MUSCLE BIOPSY; MUSCLE CELL; MUSCLE WEAKNESS; NONHUMAN; OXIDATIVE STRESS; PAIRED HELICAL FILAMENT; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SHORT SURVEY;

AGE FACTORS; ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; AUTOPHAGY; BIOPSY; ENDOPLASMIC RETICULUM; HUMANS; LYSOSOMES; MICROSCOPY, ELECTRON; MUSCLE FIBERS, SKELETAL; MUSCLES; MYOSITIS, INCLUSION BODY; MYOSTATIN; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN CONFORMATION; PROTEOSTASIS DEFICIENCIES; SIRTUIN 1; TAU PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 79953792495     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2010.11.024     Document Type: Short Survey

References (162)

1. Askanas V., Engel W.K. Inclusion-body myositis: muscle fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains. Acta Neuropathol 2008, 116(6):583-595.
2. Askanas V., Engel W.K., Nogalska A. Inclusion body myositis: a degenerative muscle disease associated with intramuscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol 2009, 19(3):493-506.
3. Askanas V., Engel W.K. Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. Curr Opin Rheumatol. 2007, 19(6):550-559.
4. Askanas V., Engel W.K. Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology. 2006, 66(2):S39-S48.
5. Askanas V., Engel W.K. Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol. 2001, 60(1):1-14.
6. Askanas V., Engel W.K. Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-beta, misfolded proteins, predisposing genes, and aging. Curr Opin Rheumatol. 2003, 15(6):737-744.
7. Engel W.K., Askanas V. Inclusion-body myositis: clinical, diagnostic, and pathologic aspects. Neurology. 2006, 66(2):S20-S29.
8. Amouri R., Driss A., Murayama K., Kefi M., Nishino I., Hentati F. Allelic heterogeneity of GNE gene mutation in two Tunisian families with autosomal recessive inclusion body myopathy. Neuromuscul Disord. 2005, 15(5):361-363.
9. Askanas V., Engel W.K. Hereditary inclusion body myopathies. The molecular and genetic basis of neurologic and psychiatric disease 2008, 524-531. Lippincott Williams & Wilkins, Wolters Kluver. 4th ed. R.N. Rosenberg, S. Di Mauro, H.L. Paulson, L. Ptacek, E.J. Nestler (Eds.).
10. Krause S., Schlotter-Weigel B., Walter M.C., Najmabadi H., Wiendl H., Muller-Hocker J., et al. A novel homozygous missense mutation in the GNE gene of a patient with quadriceps-sparing hereditary inclusion body myopathy associated with muscle inflammation. Neuromuscul Disord. 2003, 13(10):830-834.
11. Askanas V., Engel W.K. Inclusion-body myositis and myopathies: different etiologies, possibly similar pathogenic mechanisms. Curr Opin Neurol. 2002, 15(5):525-531.
12. Askanas V., Engel W.K. Unfolding story of inclusion-body myositis and myopathies: role of misfolded proteins, amyloid-beta, cholesterol, and aging. J Child Neurol. 2003, 18(3):185-190.
13. Mendell J.R., Campbell K., Rodino-Klapac L., Sahenk Z., Shilling C., Lewis S., et al. Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med. 2010, 363(15):1429-1437.
14. Moore M.J., Flotte T.R. Autoimmunity in a genetic disease-a cautionary tale. N Engl J Med. 2010, 363(15):1473-1475.
15. Page L.J., Suk J.Y., Bazhenova L., Fleming S.M., Wood M., Jiang Y., et al. Secretion of amyloidogenic gelsolin progressively compromises protein homeostasis leading to the intracellular aggregation of proteins. Proc Natl Acad Sci U S A 2009, 106(27):11125-11130.
16. Benveniste O., Guiguet M., Freebody J., Herson S., Dubourg O., Squier W., et al. Immunosupresive-treatment does not alter natural history of sporadic-inclusion body myositis (sIBM): the Pitie-Salpetriere/Oxford study. Acta Myol. 2010, 29:144-1445.
17. Dalakas M.C. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010, 6(3):129-137.
18. Griggs R.C. The current status of treatment for inclusion-body myositis. Neurology. 2006, 66(2 Suppl. 1):S30-S32.
19. Bossy-Wetzel E., Schwarzenbacher R., Lipton S.A. Molecular pathways to neurodegeneration. Nat Med. 2004, 10(Suppl.):S2-S9.
20. Fratta P., Engel W.K., McFerrin J., Davies K.J.A., Lin S.W., Askanas V. Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in AbPP-overexpressing cultured human muscle fibers. Am J Pathol. 2005, 167:517-526.
21. Hindle J.V. Ageing neurodegeneration and Parkinson's disease. Age Ageing. 2010, 39(2):156-161.
22. Keller J.N., Hanni K.B., Markesbery W.R. Impaired proteasome function in Alzheimer's disease. J Neurochem. 2000, 75:436-439.
23. Lindholm D., Wootz H., Korhonen L. ER stress and neurodegenerative diseases. Cell Death Differ. 2006, 13(3):385-392.
24. Nogalska A., D'Agostino C., Terracciano C., Engel W.K., Askanas V. Impaired autophagy in sporadic inclusion-body myositis and in endoplasmic reticulum stress-provoked cultured human muscle fibers. Am J Pathol. 2010, 177:1377-1387.
25. Nogalska A., Engel W.K., McFerrin J., Kokame K., Komano H., Askanas V. Homocysteine-induced endoplasmic reticulum protein (Herp) is up-regulated in sporadic inclusion-body myositis and in endoplasmic reticulum stress-induced cultured human muscle fibers. J Neurochem. 2006, 96(5):1491-1499.
26. Sherman M.Y., Goldberg A.L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 2001, 29(1):15-32.
27. Terracciano C., Nogalska A., Engel W.K., Wojcik S., Askanas V. In inclusion-body myositis muscle fibers Parkinson-associated DJ-1 is increased and oxidized. Free Radic Biol Med. 2008, 45(6):773-779.
28. Vattemi G., Engel W.K., McFerrin J., Askanas V. Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. Am J Pathol. 2004, 164(1):1-7.
29. Martinez-Vicente M., Cuervo A.M. Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol. 2007, 6(4):352-361.
30. Engel W.K., Cunningham G.G. Rapid examination of muscle tissue and improved trichrome method for fresh-frozen biopsy sections. Neurology. 1963, 13:919-923.
31. Engel W.K. The essentiality of histo- and cytochemical studies of skeletal muscle in the investigation of neuromuscular disease. Neurology. 1962, 12:778-794.
32. Askanas V., Engel W.K., Alvarez R.B. Enhanced detection of congo-red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer's disease using fluorescence technique. Neurology. 1993, 43(6):1265-1267.
33. Vattemi G., Nogalska A., King Engel W., D'Agostino C., Checler F., Askanas V. Amyloid-beta42 is preferentially accumulated in muscle fibers of patients with sporadic inclusion-body myositis. Acta Neuropathol. 2009, 117(5):569-574.
34. Ellis R.J., Pinheiro T.J. Medicine: danger-misfolding proteins. Nature. 2002, 416(6880):483-484.
35. Irvine G.B., El-Agnaf O.M., Shankar G.M., Walsh D.M. Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol Med 2008, 14(7-8):451-464.
36. De Bleecker J.L., Engel A.G., Ertl B.B. Myofibrillar myopathy with abnormal foci of desmin positivity. II. Immunocytochemical analysis reveals accumulation of multiple other proteins. J Neuropathol Exp Neurol. 1996, 55(5):563-577.
37. Bjorkoy G., Lamark T., Brech A., Outzen H., Perander M., Overvatn A., et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol. 2005, 171(4):603-614.
38. Seibenhener M.L., Babu J.R., Geetha T., Wong H.C., Krishna N.R., Wooten M.W. Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol. 2004, 24(18):8055-8068.
39. Nogalska A., Terracciano C., D'Agostino C., King Engel W., Askanas V. p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. Acta Neuropathol. 2009, 118(3):407-413.
40. Mirabella M., Alvarez R.B., Bilak M., Engel W.K., Askanas V. Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies. J Neuropathol Exp Neurol. 1996, 55(7):774-786.
41. Askanas V., Alvarez R.B., Mirabella M., Engel W.K. Use of anti-neurofilament antibody to identify paired-helical filaments in inclusion-body myositis. Ann Neurol. 1996, 39(3):389-391.
42. Askanas V., Serdaroglu P., Engel W.K., Alvarez R.B. Immunocytochemical localization of ubiquitin in inclusion body myositis allows its light-microscopic distinction from polymyositis. Neurology. 1992, 42(2):460-461.
43. Prayson R.A., Cohen M.L. Ubiquitin immunostaining and inclusion body myositis: study of 30 patients with inclusion body myositis. Hum Pathol. 1997, 28:887-892.
44. Engel W.K., Cunningham G.G. Alkaline phosphatase-positive abnormal muscle fibers of humans. J Histochem Cytochem. 1970, 18(1):55-57.
45. Askanas V., Engel W.K. Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis. Curr Opin Rheumatol. 1998, 10(6):530-542.
46. Askanas V., Alvarez R.B., Engel W.K. Beta-amyloid precursor epitopes in muscle fibers of inclusion body myositis. Ann Neurol. 1993, 34(4):551-560.
47. Küsters B., van Hoeve B., Schelhaas H., ter Laak H., van Engelen B., Lammens M. TDP-43 accumulation is common in myopathies with rimmed vacuoles. Acta Neuropathol. 2009, 117(2):209-211.
48. Olive M., Janue A., Moreno D., Gamez J., Torrejon-Escribano B., Ferrer I. TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol. 2009, 68(3):262-273.
49. Weihl C.C., Temiz P., Miller S.E., Watts G., Smith C., Forman M., et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2008, 79(10):1186-1189.
50. Salajegheh M., Pinkus J.L., Taylor J.P., Amato A.A., Nazareno R., Baloh R.H., et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve. 2009, 40(1):19-31.
51. D'Agostino C, Nogalska A, Engel WK, Askanas V. In sporadic inclusion-body myositis muscle fibres TDP-43-positive inclusions are less frequent and robust than p62-inclusions, and are not associated with paired helical filaments. Neuropathol Appl Neurobiol. 2010: doi:10.1111/j.365-2990.010.01108.x.
52. Ciechanover A. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Neurology 2006;(66):7-19.
53. Cuervo A.M., Wong E.S., Martinez-Vicente M. Protein degradation, aggregation, and misfolding. Mov Disord. 2010, 25(S1):S49-S54.
54. Shacka J.J., Roth K.A., Zhang J. The autophagy-lysosomal degradation pathway: role in neurodegenerative disease and therapy. Front Biosci. 2008, 13:718-736.
55. Wong E., Cuervo A.M. Autophagy gone awry in neurodegenerative diseases. Nat Neurosci. 2010, 13(7):805-811.
56. Cuervo A.M. Autophagy and aging: keeping that old broom working. Trends Genet. 2008, 24(12):604-612.
57. Glabe C.G., Kayed R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology. 2006, 66(2 Suppl. 1):S74-S78.
58. Kopito R.R., Ron D. Conformational disease. Nat Cell Biol. 2000, 2(11):E207-E209.
59. Askanas V, Engel WK, Nogalska A. Pathogenesis of sporadic inclusion-body myositis: role of cellular ageing and muscle-fibre degeneration associated with proteasomal and lysosomal inhibition, and accumulation of proteins that are also accumulated in brains of Alzheimer and Parkinson patients. Possible treatment avenues. In: Askanas V, Engel WK, editors. Muscle ageing, inclusion-body myositis and myopathies. Wiley-Blackwell; 2011 (in press).
60. Martinez A., Portero-Otin M., Pamplona R., Ferrer I. Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates. Brain Pathol. 2010, 20(2):281-297.
61. Yang C.C., Alvarez R.B., Engel W.K., Askanas V. Increase of nitric oxide synthases and nitrotyrosine in inclusion-body myositis. Neuroreport. 1996, 8(1):153-158.
62. Reynolds M.R., Berry R.W., Binder L.I. Site-specific nitration and oxidative dityrosine bridging of the tau protein by peroxynitrite: implications for Alzheimer's disease. Biochemistry. 2005, 44(5):1690-1700.
63. Zhang Y.J., Xu Y.F., Chen X.Q., Wang X.C., Wang J.Z. Nitration and oligomerization of tau induced by peroxynitrite inhibit its microtubule-binding activity. FEBS Lett. 2005, 579(11):2421-2427.
64. Askanas V., Engel W.K., Alvarez R.B. Light and electron microscopic localization of beta-amyloid protein in muscle biopsies of patients with inclusion-body myositis. Am J Pathol. 1992, 141(1):31-36.
65. Askanas V., Engel W.K., Alvarez R.B., Glenner G.G. Beta-amyloid protein immunoreactivity in muscle of patients with inclusion-body myositis. Lancet. 1992, 339(8792):560-561.
66. Askanas V., Engel W.K. Does overexpression of betaAPP in aging muscle have a pathogenic role and a relevance to Alzheimer's disease? Clues from inclusion body myositis, cultured human muscle, and transgenic mice. Am J Pathol. 1998, 153(6):1673-1677.
67. Askanas V., Engel W.K., Yang C.C., Alvarez R.B., Lee V.M., Wisniewski T. Light and electron microscopic immunolocalization of presenilin 1 in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal-recessive inclusion-body myopathy. Am J Pathol. 1998, 152(4):889-895.
68. Vattemi G., Engel W.K., McFerrin J., Buxbaum J.D., Pastorino L., Askanas V. Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis. Lancet. 2001, 358(9297):1962-1964.
69. Vattemi G., Engel W.K., McFerrin J., Pastorino L., Buxbaum J.D., Askanas V. BACE1 and BACE2 in pathologic and normal human muscle. Exp Neurol. 2003, 179(2):150-158.
70. Vattemi G., Kefi M., Engel W.K., Askanas V. Nicastrin, a novel protein participating in amyloid-beta production, is overexpressed in sporadic inclusion-body myositis muscle. Neurology. 2003, 60:A315.
71. Terracciano C., Nogalska A., Engel W.K., Askanas V. In AbetaPP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AbetaPP751 and GSK3beta activation: effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis. J Neurochem. 2010, 112:389-396.
72. Chang K.A., Kim H.S., Ha T.Y., Ha J.W., Shin K.Y., Jeong Y.H., et al. Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration. Mol Cell Biol. 2006, 26(11):4327-4338.
73. Lee M.S., Kao S.C., Lemere C.A., Xia W., Tseng H.C., Zhou Y., et al. APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol. 2003, 163(1):83-95.
74. Chromy B.A., Nowak R.J., Lambert M.P., Viola K.L., Chang L., Velasco P.T., et al. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry. 2003, 42(44):12749-12760.
75. El-Agnaf O.M., Mahil D.S., Patel B.P., Austen B.M. Oligomerization and toxicity of beta-amyloid-42 implicated in Alzheimer's disease. Biochem Biophys Res Commun. 2000, 273(3):1003-1007.
76. Ferreira S.T., Vieira M.N., De Felice F.G. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life. 2007, 59(4-5):332-345.
77. Glabe C. Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease. J Mol Neurosci. 2001, 17(2):137-145.
78. LaFerla F.M., Green K.N., Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci. 2007, 8(7):499-509.
79. Nogalska A., D'Agostino C., Engel W.K., Klein W.L., Askanas V. Novel demonstration of amyloid-beta oligomers in sporadic inclusion-body myositis muscle fibers. Acta Neuropathol. 2010, 120:661-666.
80. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998, 95(11):6448-6453.
81. Klein W.L., Stine W.B., Teplow D.B. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging. 2004, 25(5):569-580.
82. Vattemi G., Engel W.K., McFerrin J., Askanas V., Cystatin C colocalizes with amyloid-beta and coimmunoprecipitates with amyloid-beta precursor protein in sporadic inclusion-body myositis muscles. J Neurochem. 2003, 85(6):1539-1546.
83. Choi Y.C., Park G.T., Kim T.S., Sunwoo I.N., Steinert P.M., Kim S.Y. Sporadic inclusion body myositis correlates with increased expression and cross-linking by transglutaminases 1 and 2. J Biol Chem. 2000, 275(12):8703-8710.
84. Jaworska-Wilczynska M., Wilczynski G.M., Engel W.K., Strickland D.K., Weisgraber K.H., Askanas V. Three lipoprotein receptors and cholesterol in inclusion-body myositis muscle. Neurology. 2002, 58(3):438-445.
85. Wojcik S., Engel W.K., McFerrin J., Paciello O., Askanas V. AbetaPP-overexpression and proteasome inhibition increase alphaB-crystallin in cultured human muscle: relevance to inclusion-body myositis. Neuromuscul Disord. 2006, 16(12):839-844.
86. Derham B.K., Harding J.J. Alpha-crystallin as a molecular chaperone. Prog Retin Eye Res. 1999, 18(4):463-509.
87. Sun Y., MacRae T.H. The small heat shock proteins and their role in human disease. FEBS J. 2005, 272(11):2613-2627.
88. Honson N.S., Kuret J. Tau aggregation and toxicity in tauopathic neurodegenerative diseases. J Alzheimers Dis. 2008, 14(4):417-422.
89. Iqbal K., Liu F., Gong C.X., Alonso Adel C., Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol. 2009, 118(1):53-69.
90. Ksiezak-Reding H., Dickson D.W., Davies P., Yen S.H. Recognition of tau epitopes by anti-neurofilament antibodies that bind to Alzheimer neurofibrillary tangles. Proc Natl Acad Sci U S A 1987, 84(10):3410-3414.
91. Askanas V., Engel W.K., Bilak M., Alvarez R.B., Selkoe D.J. Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. Am J Pathol. 1994, 144(1):177-187.
92. Jicha G.A., Lane E., Vincent I., Otvos L., Hoffmann R., Davies P. A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease. J Neurochem. 1997, 69(5):2087-2095.
93. Zheng-Fischhèofer Q., Biernat J., Mandelkow E.M., Illenberger S., Godemann R., Mandelkow E. Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur J Biochem. 1998, 252(3):542-552.
94. Iqbal K., Wang X., Blanchard J., Liu F., Gong C.X., Grundke-Iqbal I. Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial. Biochem Soc Trans. 2010, 38(4):962-966.
95. Wilczynski G.M., Engel W.K., Askanas V. Association of active extracellular signal-regulated protein kinase with paired helical filaments of inclusion-body myositis muscle suggests its role in inclusion-body myositis tau phosphorylation. Am J Pathol. 2000, 156(6):1835-1840.
96. Wilczynski G.M., Engel W.K., Askanas V. Cyclin-dependent kinase 5 colocalizes with phosphorylated tau in human inclusion-body myositis paired-helical filaments and may play a role in tau phosphorylation. Neurosci Lett. 2000, 293(1):33-36.
97. Wilczynski G.M., Broccolini A., Engel W.K., Askanas V. Novel proposed role of glycogen synthase kinase 3beta in the pathogenesis of inclusion body myositis. Neurology. 2001, 56(Suppl. 3):A464.
98. Kannanayakal T.J., Mendell J.R., Kuret J. Casein kinase 1 alpha associates with the tau-bearing lesions of inclusion body myositis. Neurosci Lett. 2008, 431(2):141-145.
99. Broccolini A., Engel W.K., Alvarez R.B., Askanas V. Paired helical filaments of inclusion-body myositis muscle contain RNA and survival motor neuron protein. Am J Pathol. 2000, 156(4):1151-1155.
100. Spires-Jones T.L., Stoothoff W.H., de Calignon A., Jones P.B., Hyman B.T. Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci. 2009, 32:150-159.
101. Kitazawa M., Green K.N., Caccamo A., LaFerla F.M. Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. Am J Pathol. 2006, 168(6):1986-1997.
102. Lehman N.L. The ubiquitin proteasome system in neuropathology. Acta Neuropathol. 2009, 118:329-347.
103. Min S.W., Cho S.H., Zhou Y., Schroeder S., Haroutunian V., Seeley W.W., et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010, 67(6):953-966.
104. Wang Y., Martinez-Vicente M., Kruger U., Kaushik S., Wong E., Mandelkow E.M., et al. Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet. 2009, 18(21):4153-4170.
105. Nogalska A., D'Agostino C., Engel W.K., Davies K.J., Askanas V. Decreased SIRT1 deacetylase activity in sporadic inclusion-body myositis muscle fibers. Neurobiol Aging. 2010, 31:1637-1648.
106. Crews L., Tsigelny I., Hashimoto M., Masliah E. Role of synucleins in Alzheimer's disease. Neurotox Res. 2009, 16(3):306-317.
107. Waxman E.A., Giasson B.I. Molecular mechanisms of [alpha]-synuclein neurodegeneration. Biochim Biophys Acta Mol Basis Dis. 2009, 1792(7):616-624.
108. Askanas V., Engel W.K., Alvarez R.B., McFerrin J., Broccolini A. Novel immunolocalization of alpha-synuclein in human muscle of inclusion-body myositis, regenerating and necrotic muscle fibers, and at neuromuscular junctions. J Neuropathol Exp Neurol. 2000, 59(7):592-598.
109. Paciello O., Wojcik S., Engel W.K., McFerrin J., Askanas V. Parkin and its association with alpha-synuclein and AbetaPP in inclusion-body myositis and AbetaPP-overexpressing cultured human muscle fibers. Acta Myol 2006, 25(1):13-22.
110. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001, 293(5528):263-269.
111. Askanas V., Dalakas M.C., Engel W.K. Inclusion-body myositis: clinical and pathologic aspects, and basic research potentially relevant to treatment. Neurology. 2006, 66(2 Suppl. 1):Si.
112. Schlossmacher M.G., Frosch M.P., Gai W.P., Medina M., Sharma N., Forno L., et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol. 2002, 160:1655-1667.
113. Tsai Y.C., Fishman P.S., Thakor N.V., Oyler G.A. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J Biol Chem. 2003, 278(24):22044-22055.
114. Paciello O., Wojcik S., Engel W.K., Askanas V. Alpha-synuclein and Parkin are novel proteins accumulated in ragged-red fibers. Neuromuscul Disord. 2006, 16:657.
115. Engel W.K. "Ragged-red fibers" in opthamoplegia syndromes and their differential diagnosis. Excerpta Med Int Cong Series 1971, 237:28.
116. Oldfors A., Moslemi A.R., Jonasson L., Ohlsson M., Kollberg G., Lindberg C. Mitochondrial abnormalities in inclusion-body myositis. Neurology. 2006, 66(2 Suppl. 1):S49-S55.
117. Narendra D., Tanaka A., Suen D.F., Youle R.J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol. 2008, 183(5):795-803.
118. Wild P., Dikic I. Mitochondria get a Parkin' ticket. Nat Cell Biol. 2010, 12(2):104-106.
119. Gonzalez-Cadavid N.F., Bhasin S. Role of myostatin in metabolism. Curr Opin Clin Nutr Metab Care. 2004, 7(4):451-457.
120. Wojcik S., Engel W.K., McFerrin J., Askanas V. Myostatin is increased and complexes with amyloid-beta within sporadic inclusion-body myositis muscle fibers. Acta Neuropathol. 2005, 110(2):173-177.
121. Wojcik S., Nogalska A., McFerrin J., Engel W.K., Oledzka G., Askanas V. Myostatin precursor protein is increased and associates with amyloid-beta precursor protein in inclusion-body myositis culture model. Neuropathol Appl Neurobiol. 2007, 33(2):238-242.
122. Starck C.S., Sutherland-Smith A.J. Cytotoxic aggregation and amyloid formation by the myostatin precursor protein. PLoS ONE. 2010, 5(2):e9170.
123. Ding W.X., Yin X.M. Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome. Autophagy. 2008, 4(2):141-150.
124. Nixon R.A. Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci. 2007, 120(Pt 23):4081-4091.
125. Bedford L., Paine S., Sheppard P.W., Mayer R.J., Roelofs J. Assembly, structure, and function of the 26S proteasome. Trends Cell Biol. 2010, 20(7):391-401.
126. Voges D., Zwickl P., Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999, 68:1015-1068.
127. Voges D., Zwickl P., Baumeister W. The 26S proteasome: a molecular machine designed for controlled PRoteolysis. Annu Rev Biochem 1999, 68(1):1015-1068.
128. McNaught K.S., Belizaire R., Isacson O., Jenner P., Olanow C.W. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol. 2003, 179(1):38-46.
129. Oddo S. The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med. 2008, 12(2):363-373.
130. Cecarini V., Bonfili L., Amici M., Angeletti M., Keller J.N., Eleuteri A.M. Amyloid peptides in different assembly states and related effects on isolated and cellular proteasomes. Brain Res. 2008, 1209:8-18.
131. Tseng B.P., Green K.N., Chan J.L., Blurton-Jones M., LaFerla F.M. A[beta] inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging. 2008, 29(11):1607-1618.
132. Fratta P., Engel W.K., Van Leeuwen F.W., Hol E.M., Vattemi G., Askanas V. Mutant ubiquitin UBB+1 is accumulated in sporadic inclusion-body myositis muscle fibers. Neurology. 2004, 63(6):1114-1117.
133. Keck S., Nitsch R., Grune T., Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem. 2003, 85(1):115-122.
134. Lindersson E., Beedholm R., Hojrup P., Moos T., Gai W., Hendil K.B., et al. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem. 2004, 279(13):12924-12934.
135. Dennissen F.J.A., Kholod N., Steinbusch H.W.M., Van Leeuwen F.W. Misframed Proteins and Neurodegeneration: A Novel View on Alzheimer's and Parkinson's Diseases. Neurodegener Dis. 2010, 7(1-3):76-79.
136. He C., Klionsky D.J. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 2009, 43:67-93.
137. Nixon R.A. Autophagy in neurodegenerative disease: friend, foe or turncoat?. Trends Neurosci. 2006, 29(9):528-535.
138. Nixon R.A., Wegiel J., Kumar A., Yu W.H., Peterhoff C., Cataldo A., et al. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol. 2005, 64(2):113-122.
139. Mikol J, Engel AG. Inclusion body myositis. In: Engel AG, editor. Myology. 3rd ed. McGraw-Hill Professional; 2004. p. 1367-88.
140. Klionsky D.J., Abeliovich H., Agostinis P., Agrawal D.K., Aliev G., Askew D.S., et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 2008, 4(2):151-175.
141. Hamano T., Gendron T.F., Causevic E., Yen S.H., Lin W.L., Isidoro C., et al. Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. Eur J Neurosci. 2008, 27(5):1119-1130.
142. Koh Y.H., von Arnim C.A., Hyman B.T., Tanzi R.E., Tesco G. BACE is degraded via the lysosomal pathway. J Biol Chem. 2005, 280(37):32499-32504.
143. Yu W.H., Cuervo A.M., Kumar A., Peterhoff C.M., Schmidt S.D., Lee J.H., et al. Macroautophagy: a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol. 2005, 171(1):87-98.
144. Zhang K., Kaufman R.J. The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology. 2006, 66(2 Suppl. 1):S102-S109.
145. Zhang K., Kaufman R.J. From endoplasmic-reticulum stress to the inflammatory response. Nature. 2008, 454(7203):455-462.
146. Nogalska A., Engel W.K., Askanas V. Putative pathogenic role of the endoplasmic reticulum stress in sporadic inclusion-body myositis. Acta Myol. 2010, 29:143-144.
147. Albani D., Polito L., Forloni G. Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: experimental and genetic evidence. J Alzheimers Dis. 2010, 19(1):11-26.
148. Tang B.L. Sirt1's complex roles in neuroprotection. Cell Mol Neurobiol. 2009, 29(8):1093-1103.
149. Qin W., Yang T., Ho L., Zhao Z., Wang J., Chen L., et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem. 2006, 281(31):21745-21754.
150. Chen J., Zhou Y., Mueller-Steiner S., Chen L.F., Kwon H., Yi S., et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem. 2005, 280(48):40364-40374.
151. Julien C., Tremblay C., Emond V., Lebbadi M., Salem N., Bennett D.A., et al. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol. 2009, 68(1):48-58.
152. Yeung F., Hoberg J.E., Ramsey C.S., Keller M.D., Jones D.R., Frye R.A., et al. Modulation of NF-kappaBdependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004, 23(12):2369-2380.
153. Askanas V., Engel W.K. Molecular pathology and pathogenesis of inclusion-body myositis. Microsc Res Tech. 2005, 67(3-4):114-120.
154. Nogalska A., Wojcik S., Engel W.K., McFerrin J., Askanas V. Endoplasmic reticulum stress induces myostatin precursor protein and NF-kappaB in cultured human muscle fibers: relevance to inclusion body myositis. Exp Neurol. 2007, 204(2):610-618.
155. Choi J., Sullards M.C., Olzmann J.A., Rees H.D., Weintraub S.T., Bostwick D.E., et al. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem. 2006, 281(16):10816-10824.
156. Abou-Sleiman P.M., Muqit M.M., Wood N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci. 2006, 7(3):207-219.
157. Fink A.L. Chaperone-mediated protein folding. Physiol Rev. 1999, 79(2):425-449.
158. Pockley A.G. Heat shock proteins in health and disease: therapeutic targets or therapeutic agents?. Expert Rev Mol Med. 2001, 3(23):1-21.
159. Ozturk A., McFerrin J., Engel W., Askanas V. HSP70 chaperone machinery in sporadic-inclusion-body myositis muscle fibers. Neurology. 2004, 62:A154.
160. Askanas V., McFerrin J., Baque S., Alvarez R.B., Sarkozi E., Engel W.K. Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc Natl Acad Sci U S A 1996, 93(3):1314-1319.
161. Hashimoto M., Rockenstein E., Crews L., Masliah E. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular Med. 2003, 4(1-2):21-36.
162. Hong W.K., Han E.H., Kim D.G., Ahn J.Y., Park J.S., Han B.G. Amyloid-beta-peptide reduces the expression level of mitochondrial cytochrome oxidase subunits. Neurochem Res. 2007, 32(9):1483-1488.